Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2016; 8(11): 793-800
Published online Nov 15, 2016. doi: 10.4251/wjgo.v8.i11.793
Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening tests
Le-Le Song, Yue-Min Li
Le-Le Song, Yue-Min Li, Department of Radiotherapy, the Chinese PLA 309 Hospital, Beijing 100091, China
Le-Le Song, BioChain (Beijing) Science and Technology, Inc., Beijing 100176, China
Author contributions: All authors contributed to this manuscript.
Supported by The Beijing Municipal Science and Technology Project (capital public health project) No. Z151100003915092 sponsored by the Beijing Municipal Science and Technology Commission.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Le-Le Song, MD, PhD, Department of Radiotherapy, the Chinese PLA 309 Hospital, No. 17, Heishanhu Road, Haidian District, Beijing 100091, China.
Telephone: +86-10-66775222
Received: June 12, 2016
Peer-review started: June 17, 2016
First decision: July 30, 2016
Revised: August 1, 2016
Accepted: August 30, 2016
Article in press: August 31, 2016
Published online: November 15, 2016
Core Tip

Core tip: The choice of colorectal cancer (CRC) screening methods is crucial for screening validity and compliance. Currently, the fecal immunochemical test (FIT), fecal DNA and the blood-based SEPT9 assays are the three in vitro diagnostic tests for CRC screening. In this article, we reviewed the current application of the three types of assays and compared their performance in CRC screening. FIT is still the cheapest method with high screening validity, and fecal DNA tests also exhibit high validity but its price is high. In contrast, the SEPT9 assay showed high compliance with acceptable performance. The choice of screening test may depend on the balance of performance, compliance and costs.